Tozinameran
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2020
- First approval year
- 2020
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Tozinameran
- comirnaty
- Comirnaty
- bnt 162b2
- BNT-162B2
- bnt162b2
- Bnt162b2
- BNT162b2
- BNT162B2
- BNT162b2 (B.1.1.529)
- BNT162b2 (B.1.351)
- BNT162b2 (Omi JN.1)
- BNT162b2 (Omi KP.2)
- BNT162b2 (Omi XBB.1.5)
- BNT162b2 (Tozinameran)
- BNT162b2 20mcg
- BNT162b2 30mcg
- BNT162b2 30μg
- BNT162b2.B.1.351
- comirnaty
- Comirnaty
- COMIRNATY
- Comirnaty (BTN162b2)
- COMIRNATY intramuscular injection
- comirnaty mrna
- Comirnaty mrna
- Comirnaty®
- COMIRNATY®
And 19 more, listed on the interactive page.
- CAS registry numbers
- 2417899-77-3
- ChEMBL ID
- CHEMBL4650429
- RxNorm IDs (RxCUI)
- 2468230
- FDA ingredient codes (UNII)
- 5085ZFP6SJ
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -meran
Mechanisms of action
- Mechanism
- Spike glycoprotein vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Spike glycoprotein
- Protein identifier
- P0DTC2
Open Targets mechanisms
- Mechanism
- Spike glycoprotein vaccine antigen
- Action type
- VACCINE ANTIGEN
- Target
- Spike glycoprotein
- Condition
- Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000694
- Subject identifier
- D045169
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Hypersensitivity
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005271
- Subject identifier
- D006967
- Condition
- COVID-19
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0100096
- Subject identifier
- D000086382
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000694
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002974
- Condition identifier
- MONDO_0004952
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005062
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005100
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005109
- Condition identifier
- MONDO_0005192
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005265
- Condition identifier
- MONDO_0005271
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005301
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005554
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005575
- Condition identifier
- MONDO_0006594
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007243
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007254
- Condition identifier
- MONDO_0007256
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007915
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008054
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008315
- Condition identifier
- MONDO_0008383
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0009831
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0011429
- Highest recorded phase
- 2
And 6 more, listed on the interactive page.
- Event
- acute macular neuroretinopathy
- Reports
- 2
- Reporting signal score
- 12.0859
- Event
- bicytopenia
- Reports
- 9
- Reporting signal score
- 32.0033
- Event
- catarrh
- Reports
- 3
- Reporting signal score
- 12.2123
- Event
- cerebral venous thrombosis
- Reports
- 11
- Reporting signal score
- 39.9965
- Event
- covid-19
- Reports
- 16
- Reporting signal score
- 18.0666
- Event
- covid-19 pneumonia
- Reports
- 24
- Reporting signal score
- 87.7176
- Event
- cutaneous lupus erythematosus
- Reports
- 7
- Reporting signal score
- 20.495
- Event
- deep vein thrombosis
- Reports
- 17
- Reporting signal score
- 12.7557
- Event
- ear pruritus
- Reports
- 4
- Reporting signal score
- 11.0627
- Event
- gravitational oedema
- Reports
- 4
- Reporting signal score
- 13.5915
- Event
- hepatic cytolysis
- Reports
- 12
- Reporting signal score
- 37.4803
- Event
- idiopathic inflammatory myopathy
- Reports
- 2
- Reporting signal score
- 15.0172
- Event
- immune thrombocytopenia
- Reports
- 16
- Reporting signal score
- 62.3939
- Event
- ischaemic stroke
- Reports
- 29
- Reporting signal score
- 66.5488
- Event
- jugular vein thrombosis
- Reports
- 5
- Reporting signal score
- 15.2547
- Event
- myocarditis
- Reports
- 13
- Reporting signal score
- 29.7395
- Event
- myositis
- Reports
- 7
- Reporting signal score
- 11.7451
- Event
- ophthalmic herpes zoster
- Reports
- 5
- Reporting signal score
- 15.2547
- Event
- pancreatitis acute
- Reports
- 10
- Reporting signal score
- 10.6669
- Event
- pericarditis
- Reports
- 10
- Reporting signal score
- 17.5988
- Event
- petechiae
- Reports
- 8
- Reporting signal score
- 14.2961
- Event
- piloerection
- Reports
- 4
- Reporting signal score
- 15.3661
- Event
- portosplenomesenteric venous thrombosis
- Reports
- 2
- Reporting signal score
- 11.0349
- Event
- pulmonary embolism
- Reports
- 59
- Reporting signal score
- 100.697
- Event
- pyrexia
- Reports
- 42
- Reporting signal score
- 16.1793
And 12 more, listed on the interactive page.
- NCT04368728
- NCT04569383
- NCT04588480
- NCT04649021
- NCT04713553
- NCT04780659
- NCT04800133
- NCT04816643
- NCT04816669
- NCT04860739
- NCT04889209
- NCT04894435
- NCT04895982
- NCT04907331
- NCT04949490
- NCT04952402
- NCT04955626
- NCT04961229
- NCT04969250
- NCT05047640
- NCT05049226
- NCT05057169
- NCT05057182
- NCT05084989
- NCT05124171
And 36 more, listed on the interactive page.
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (142)
- A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19
- A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19
- A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults
- A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
- A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster
- A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.
- A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine
- A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine
- A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine
- A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine Among Children in Brazil
- A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil
- A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine
- A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults
- A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years
- A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza
- A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
- A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults
- A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
- A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
Approved for (2)
In development for (2)
- Allergic disease Phase 2
- Cancer Phase 2